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RampUPFormalin-ﬁxed parafﬁn-embedded (FFPE) tissue samples are a potentially valuable resource of expression
information for medical research, but are under-utilized due to degradation and modiﬁcation of the RNA.
Using a random primer-based RNA ampliﬁcation strategy, we have evaluated multiple protocols for the
extraction and isolation of RNA from FFPE samples. We found that the RecoverAll RNA isolation procedure
with three or four slices (ten-microns in thickness), supplemented with additional DNAse, gave optimal
results. RNA integrity as assessed by Agilent Bioanalyzer, and ampliﬁcation of the 28S ribosomal RNA, were
predictive for the number of genes detected on Affymetrix arrays. We obtained expression data for colon and
lung tumor and normal FFPE samples and matched frozen samples and found a high correlation between
frozen and matched FFPE samples (R2 between 0.82 and 0.89), while the signature sets in tumor versus
normal comparisons were also quite similar. QPCR conﬁrmed all 16 of the differential expression results from
the microarrays that we tested. Differentially expressed signature genes from tumor versus matched normal
FFPE tissue from colon and lung were identiﬁed as cancer-related, with 95 colon tumor and 67 lung tumor
genes identiﬁed, respectively.
© 2009 Elsevier Inc. All rights reserved.Introduction
Genome-wide studies of disease usingmicroarrays can extensively
investigate the characteristics and molecular causes of disease by
comparing gene expression in normal tissue samples to gene
expression in disease tissue. To further deﬁne disease progression or
disease states, specimens with varying degrees of pathology can be
compared. These studies can identify markers of disease, ﬁnd
indicators of disease progression, generate targets for therapy, and
lead to tools for stratiﬁcation of patients for speciﬁc therapeutic
strategies. To optimally perform these comparisons, samples need to
be characterized according to disease state using the best cytological
and histological tools available. Often in the area of cancer diagnosis,
this requires the use of formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue sections, which present a major obstacle since RNA isolated
from these sections is not of satisfactory quality [1]. During FFPE tissue
processing, isolated samples are placed in formalin (typically
overnight or longer), and then embedded in parafﬁn. While this
ﬁxation process preserves the tissue, these steps can lead to
degradation and chemical modiﬁcations of the RNA with extensive
cross-links between biomolecules, hindering analysis [1–5]. Conse-
quently, these samples, which are archived for years and evenAnderson).
ll rights reserved.decades, have not yet been fully leveraged as a research tool even
though they represent a vast collection of tissue specimens that have
accompanying histological data (often associated with clinical
outcome data). Therefore, the application of large-scale genomic
tools for molecular analysis of these samples is a signiﬁcant milestone
of pathological research that has been recently investigated through a
variety of approaches [6–12].
The focus of our study is the identiﬁcation of techniques for the
isolation of RNA from FFPE samples to obtain useful expression data
using microarrays. Recent technological developments have en-
hanced the capabilities of RNA isolation from FFPE samples, improving
RNA yields [1,5–13]. Still, the RNA yield continues to be low and it is
often partially or signiﬁcantly degraded. Consequently, ampliﬁcation
of FFPE RNA is critical for expression studies. There are a number of
suitable techniques for ampliﬁcation of RNA from FFPE samples for
microarray analysis (for example, those designed by Nugen, Qiagen,
Arcturus, Epicentre, and Genisphere). We decided to focus on the
Genisphere 2 round ampliﬁcation process, RampUP, as this ampliﬁ-
cation technique has been optimized to amplify degraded (FFPE) RNA
samples by using both dT and random primers in the initial reverse
transcription to preserve as much transcript information as possible
and minimize any 3′or 5′mRNA ampliﬁcation bias. This ampliﬁcation
strategy is suitable for small input samples sizes (b50 ng total RNA),
accurately represents the expression proﬁle of the original RNA
sample, and has an optimized workﬂow to produce labeled antisense
cDNA for array hybridization (total time: 5 h on day 1, 3 h on day 2,
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250 ng), this method can be simpliﬁed to 1 ampliﬁcation step
reducing the total time to 1.5 days to produce labeled antisense cDNA
[14]. In this report, we describe modiﬁed and enhanced FFPE RNA
isolation techniques followed by RNA ampliﬁcation and labeling to
generate RNA expression data. We analyzed this data and found that
the results were robust and reproducible, compared well to matched,
frozen samples, and identiﬁed expression differences that were
biologically relevant to cancer and the speciﬁc types of cancer and
tissues examined in the study.
Results
Identiﬁcation of optimal RNA isolation techniques
To identify the optimal RNA isolation techniques for our purposes,
we evaluated ﬁve approaches for RNA isolation: RecoverAll for FFPE
(Ambion, Austin TX), ParadiseWhole Transcript (Arcturus Bioscience,
Mountain View, CA), Purelink FFPE RNA isolation (Invitrogen,
Carlsbad, CA), High Pure RNA Parafﬁn (Roche, Nutley, NJ), and
FormaPure (Agencourt Bioscience Corporation, Beverly MA). All of
these procedures, except FormaPure, require a deparafﬁnization step,
which has routinely been accomplished by treatment with Xylene.
However, a more environmental-friendly solution, D-limonene
(Hemo-De) can be used [15], prompting us to perform a side-by-
side comparison of these solutions for deparafﬁnization on 6 FFPE
tissues. Both solutions had similar RNA yields (an average of 1.4 μg for
Xylene and an average of 1.6 μg for Hemo-De total) and quality as
assessed by quantitative PCR (QPCR) (Supplementary Figure 1), so we
conducted our experiments with the Hemo-De solution.
The ﬁve RNA isolation procedures were tested on human tissue
sections from multiple FFPE blocks obtained from the Cooperative
Human Tissue Network (CHTN, Ohio State University), as shown in
Table 1. In parallel, matching fresh-frozen samples were isolated using
standard procedures with Qiazol (as described in Materials and
methods). All samples were analyzed with the Agilent Bioanalyzer,
and as expected, the FFPE samples demonstrated varying degrees of
degradation. Bioanalyzer software assigns an RNA integrity (RIN)
score, from 10 (highest integrity) to 2 (lowest integrity), based on the
entire electrophoretic trace, including ribosomal bands and degrada-
tion products, of the RNA sample. The FFPE samples used in this studyTable 1
Sample information.
Sample name Source Prep timea (min) Year tissue har
Lung n1 Lung natb 20 2006
Colon n1 Colon nat 30 2005
Colon ca2 Colon cancer pt 1 30 2006
Colon n2 Colon nat to colon ca2 30 2006
Colon ca3 Colon cancer pt 2 30 2003
Lung n2 Lung nat 20 2006
Lung n3 Lung nat 15 2005
Lung n4 Lung nat 30 2003
Colon Bcell ca1 Colonic large B cell lymphoma 15 2004
Colon ca4 Colon cancer 10 2005
Colon ca5 Colon cancer na 2003
Colon n3 Colon nat 15 2006
Renal ca1 Renal cell carcinoma na 2005
Lung adeno ca1 Lung adenocarcinoma 30 2006
Colon ca6 Colon cancer 15 2004
Colon n4 Colon diverticulitis 20 2006
Lung sq ca1 Lung squamous cell carcinoma na 2006
Lung sq n1 Lung nat to lung sq ca1 na 2006
a The time between when the “frozen tissue” was resected and when the sample was pl
b nat refers to normal adjacent tissue, pt is patient.
c Usage code is I: used for comparison of different RNA isolation techniques, A: samples use
from the same tissue sample).
d Rin Scores are shown for RNA isolated using the RecoverAll technique. Values for the o
FormaPure technique. The nd is a sample that was not determined as only 1 28S band washad RIN scores from 6.8 (distinct 18S and 28S rRNA bands) to 2.2 (no
detectable rRNA bands) as shown in Table 1. For the FFPE tissues that
did not have 2 ribosomal bands (likely due to signiﬁcant cross-linking
from ﬁxation) and low RIN scores, we used the following parameters
as cut-offs for moving forward with the isolation technique: A ratio of
Beta actin (ACTB) QPCR 3′ amplicon to 5′ amplicon of less than 20, a
differential of less than 7 Ct between the ACTB 5′ amplicon of the
sample and the Universal Control RNA (Fig. 1), and greater than
500 ng average yield. Based on these parameters, the RecoverAll, and
Whole Transcript protocols gave RNA with satisfactory quality and
sufﬁcient yields for the downstream procedures (Fig. 1), and in a
separate experiment on different samples, the FormaPure kit also
produced satisfactory RNA and yields that met the cut-offs described
above (Fig. 2). Similar results were obtained in multiple experiments
with different FFPE blocks of varying ages (data not shown). Although
previous reports have cited reproducibility issues with the RecoverAll
procedure, when the tissue input was limited to fewer than the
maximum of 10 μm eight sections [16], we obtained optimal RNA
yields with the RecoverAll procedure when either three or four
sections were used rather than eight. One issue we observed with the
RecoverAll RNA isolation procedure was DNA carry-over in the
puriﬁed RNA, resulting in misleading results in some of the RNA
quality control tests using QPCR. To eliminate DNA carry-over in the
puriﬁed RNA, we doubled the DNase I concentration. This improved
the efﬁciency of the DNA removal by 1000-fold, as determined by
QPCR of the ACTB gene compared to a no reverse transcriptase
reaction (data not shown). The optimized DNase I conditions were
therefore used for subsequent experiments.
Since both the optimized RecoverAll and the FormaPure proce-
dures have signiﬁcantly shorter processing time, they were ideal for
further optimization as methods to isolate RNA from FFPE tissues for
microarray analysis on Affymetrix arrays.
Biological variation of the RecoverAll and FormaPure techniques
was evaluated by processing replicates of serial sections from the
same block. For both of these RNA isolation procedures, similar yields
and purity, based on spectrophotometric analysis, were obtained for
all but one of the tissues tested (Fig. 2). In addition, the variance of
RNA yields per tissue section amongst biological replicate samples
was lower (average coefﬁcient of variation of 34% with a range from
28% to 52%) than has been previously reported with un-optimized
protocols with the RecoverAll procedure and high tissue input [16].vested 10 μm FFPE sections Frozen tissue (mg) Usage codec RINd score
3 80 I 6.8
3 60 I/A 2.4
3 100 I/A 5.6
3 120 I 5.2
3 80 I 2.5
3 100 I nd
3 100 I 2.5
3 100 I 2.2
4 160 I 2.5
4 84 I 2.0
4 125 I 2.2
4 158 I 2.2
3 30 I/H 2.6
3 50 I/H 2.4
3 50 I/H 2.4
3 50 I/H 2.5
3 50 I/H 2.3
3 50 I/H 2.2
aced in liquid nitrogen, and na indicates that the information is not available.
d for replicate ampliﬁcation studies, H: within tissue heterogeneity (multiple isolations
ther techniques were within two tenths except for renal ca1, which was 1.5 with the
visible.
Fig. 1. RNA quality analysis. RNA was isolated from 10 μm sections of six 1- to 3-year-old colon and lung FFPE tissues using the procedures indicated. In A, the FFPE RNAwas assessed
for yield by spectrophotometric analysis and total RNA yield was adjusted per each 10 μm tissue section of input. The average and standard deviation (in parentheses) for all 6 tissues
is shown. The 3′ to 5′ ratio was assessed by QPCR using a primer set located at the 3′ end of the transcript and another located 300 bases upstream. ACTB 5′ (Beta actin) delta Ct (the Ct
of the FFPE sample minus the Ct 100 ng of Universal cell line control for the ACTB 5′ amplicon) is shown. Averages with a “⁎” are for only 3 samples due to low yields in the other 3
samples. Shown in B are the Agilent Bioanalyzer traces from RNA isolated from an FFPE colon tumor sample using the modiﬁed RecoverAll protocol (left), the same FFPE tissue
isolated using the Whole Transcript kit (center), and a matched fresh-frozen colon cancer sample isolated by Qiazol (right).
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To focus on samples likely to yield satisfactory results before
running the microarray, we examined multiple characteristics
(Supplementary Table S1) of the samples to ﬁnd the best predictor
of success on the microarray, as deﬁned by percent present calls.
These characteristics included RNA integrity, RNA purity, target yields,
and ampliﬁcation characteristics of the RNA samples. RNA with RIN
scores greater than 4 (distinct 18s and 28s ribosomal peaks on the
Agilent Bioanalyzer) yielded satisfactory results by microarray when
using a non-3′ bias ampliﬁcation protocol such as RampUP (Geni-
sphere). For samples with RIN scores less than 4, we evaluated a
number of parameters to determine the most accurate in predicting
percent present calls. These included QPCR-based assays such as 5′
ACTB (Delta Ct), 3′ to 5′ ACTB ratio, or a combination of these values
(as shown in Supplementary Table S2). We found QPCR of the 28S
rRNA gene had a good correlation (R2=0.75) to percent present calls
in microarrays from samples that included lung, colon, and renal
tumor and normal tissues (Fig. 3). Speciﬁcally, under these conditions,Fig. 2. Side-by-side comparison of RNA yield and purity from RNA isolated with the
FormaPure and the modiﬁed RecoverAll techniques. Sections from six FFPE human
tissue blocks were processed and total RNA yield and purity were determined as in Fig.
1. The bars represent the average total RNA yield (ng/tissue section) and standard
deviation from 4 biological replicates (modiﬁed RecoverAll,) or 2 biological replicates
(FormaPure,). The line graph is a representative value for purity (A260/A280) from one
biological replicate for each tissue.we found that when the delta Ct of the samples was less than 15 in
relationship to the same concentration of Universal control RNA, 21
out of 24 samples had greater than 40% present calls. In contrast, of
the samples that had a delta Ct value greater than 15, only 3 out of
8 had greater than 40% present calls on the microarray. For tissues
other than colon or lung, the optimal control genes may be different
based on the consistency of the expression of that gene; however, the
ability of the nucleic acid to be ampliﬁed is likely critical for successful
expression analysis.
RNA ampliﬁcation and microarray analysis
RNA from FFPE samples isolated with the RecoverAll and
FormaPure procedures, as well as RNA from fresh-frozen samples
isolated with Qiazol were ampliﬁed and labeled using the RampUP
technique and analyzed by expression proﬁling on Affymetrix HG-
U133A v 2.0 microarrays. The results from these arrays indicate that
these FFPE RNA isolation procedures generate data of a similar quality,
with a higher percent of probe sets present for samples isolated with
the RecoverAll technique (Table 2). However, the FFPE samples still
had a lower percentage of probe sets present compared to the
matched, fresh-frozen samples.
We next wanted to determine how reproducible the RampUP
method of ampliﬁcation was for both fresh-frozen and FFPE RNA. Two
fresh-frozen and two FFPE RNA samples were ampliﬁed and labeled inFig. 3. RNA quality assessment comparison to microarray results. The delta Ct for 28S
ribosomal RNA (the Ct of the FFPE sample minus the Ct of 100 ng of Universal cell line
control for the 28S amplicon) for 38 individual ampliﬁcation reactions (from samples
listed in Table 1) was compared to the number of percent present calls on Affymetrix
HG-U133A version 2.0 microarrays. Data is shown for FFPE samples (solid diamonds)
and fresh-frozen samples (open diamonds).
Table 2
Quality control results for arrays from FFPE samples isolated by RecoverAll and FormaPure.
Sample type (arrays) RNA isolation method Labelled cDNA yielda (μg) Scale factorb Back-ground Percent probesets present GAPDH 3′/5′ ratioc
FFPE (20) RecoverAll 14.8 (3.4) 2.6 (0.6) 33.0 (2.9) 46.1 (6.1) 2.8 (0.9)
FFPE (12) FormaPure 15.7 (2.9) 2.6 (0.7) 32.2 (1.9) 41.1 (7.5) 3.0 (1.3)
Frozen (11) Qiazol 15.9 (2.2) 0.6 (0.2) 36.9 (1.7) 64.1 (1.5) 1.8 (0.5)
a For each parameter, the average for all of the samples is shown. Values in parentheses are the standard deviation of the average.
b The scale factor is used by Affymetrix to adjust arrays to a constant target mean.
c The ratio for each array is the relative amounts as described in Materials and methods.
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of these experiments are summarized in Supplementary Table S3. In
general we observed that fresh-frozen samples ampliﬁed more
efﬁciently, yielding greater than 40% more ampliﬁed RNA, compared
to FFPE-extracted RNA. Among replicates for each sample, the
ampliﬁcation yield varied by 7–9%. After preparation of biotinylated
cDNA and hybridization to arrays, we observed 59% +/− 0.5% and
60% +/− 1% present calls for the two fresh-frozen samples and 33%
+/− 4% and 49% +/− 1% for the two FFPE samples. We also
compared the raw signal intensities across the replicates for each
feature and calculated the coefﬁcient of variation (CV) for each RNA
sample. The CVs were 22% and 25% for fresh frozen normal and tumor
samples, and 30% and 34% for FFPE normal and tumor samples. This
result was expected, given that the FFPE samples were signiﬁcantly
degraded based on analysis on a Bioanalyzer. Still, the average
correlation coefﬁcients were 0.98 for frozen samples, and 0.88 for
highly degraded (RIN=2.4) FFPE samples to 0.95 for moderately
degraded (RIN=5.6) FFPE samples. Finally, we compared the
RampUP procedure directly to the Affymetrix standard procedure.
Even though these are two very different ampliﬁcation protocols, we
observed correlation coefﬁcient of 0.86 between frozen samples
prepared with the standard Affymetrix procedure compared to the
same sample prepared with RampUP. The variation was higher, with a
correlation coefﬁcient of 0.65, when frozen samples preparedwith the
standard Affymetrix procedure was compared to FFPE samples
prepared with RampUP (Supplementary Table S5).
Direct comparisons of arrays from matched FFPE and fresh-frozen
samples
A direct comparison of expression proﬁles from FFPE samples and
fresh-frozen samples is technically difﬁcult to achieve, as sections of
tissues that are often heterogeneous in nature [17–19] have to be
separated and processed independently. To approximate this type of
comparison, we compared matched FFPE and fresh-frozen samples
from the same patient. For reference, we also generated expression
proﬁles for adjacent slices from the same tissue processed in the same
manner (fresh-frozen versus fresh-frozen, and FFPE versus FFPE),
providing a more idealized comparison and a minimum expected
variation from one sample to the next (adjacent or near adjacent
slices). This more idealized comparison for 43 microarrays run on 12
different samples had correlation coefﬁcients ranging from 0.975 to
0.985 for fresh-frozen versus fresh-frozen, and 0.887 to 0.962 for FFPE
versus FFPE, which represents the expected upper limit of correlation
(Supplementary Figure S2). When FFPE samples were compared to
matched fresh-frozen samples, the correlation coefﬁcients dropped
off only a little with samples derived from RNA isolated using the
RecoverAll procedure (0.82 to 0.89), while a lower range of
correlation coefﬁcients (0.63 to 0.89) were obtained when samples
were derived from RNA isolated using the FormaPure procedure
(Supplementary Figure S2).
Comparison of FFPE signatures to fresh-frozen biosignatures
It is critical that the analysis of FFPE tissue generates useful sets
of genes that are differentially expressed between two differenttypes of samples, such as normal versus tumor tissue. Therefore, the
expression differences, or biosignatures, generated by comparisons
of FFPE samples must reﬂect true expression differences. To further
examine the consistency of comparative biosignatures, we generat-
ed the biosignatures (genes with greater than 2-fold changes and p-
values less than 0.001) of normal colon versus colon tumor tissues
using FFPE samples, to generate results as if the experiment were
done only with FFPE material. In parallel, we generated an
expression biosignature of expression differences of colon normal
versus colon tumor tissues from matched, fresh-frozen samples, as if
the experiment were done only with frozen material. As expected,
there was little variation (R2=0.99) in biosignatures between
replicates of the fresh-frozen samples (Fig. 4C), and basically the
same variation (R2=0.98) between replicates of the FFPE samples
(Fig. 4A). However, when comparing the biosignatures of the fresh-
frozen to FFPE, we observed more variation (R2=0.89). When the
biosignature thresholds are made more stringent, similar results are
obtained; however, using less stringent cut-offs led to lower
concordance, likely due to the inclusion of false positives. To put
this correlation in context of biological differences, we compared
the biosignature from the colon tumor samples to the biosignature
from lung tumor samples. We would expect there to be some
correlation between these biosignatures as tumor-speciﬁc gene
expression should have some similarity; however, when comparing
biosignatures from different tissue types, we would expect
signiﬁcant discordance. Therefore, as expected, we observed a
correlation coefﬁcient of 0.46 between the frozen colon tumor
versus normal biosignature genes and the frozen lung tumor versus
normal biosignature genes (Supplementary Figure S3A). A similar
comparison of the FFPE colon tumor biosignature genes versus the
lung tumor biosignature genes had an R2 of 0.39 (Supplementary
Figure S3B).
Veriﬁcation of expression results
As described above, we compared biosignature genes from the
FFPE samples to the biosignature genes from the fresh-frozen
samples and found a signiﬁcant overlap (correlation coefﬁcient of
0.89), conﬁrming most of the results; however, there was still some
variation between the FFPE and fresh-frozen results. To help resolve
some of the discrepancies between the biosignatures from the FFPE
and fresh-frozen samples, and also to conﬁrm some of the common
ﬁndings between the two sample types, we tested the RNA samples
for expression using QPCR. We chose 16 random genes that were
differentially expressed (N2-fold changes, Pb0.001) between the
tumor and normal samples, including two genes that had signiﬁcant
expression differences in the opposite direction between the FFPE
experiment and the fresh-frozen experiment, and 3 genes that were
signiﬁcantly differentially expressed in the FFPE experiment and
unchanged in the fresh-frozen. Signiﬁcantly, we found that all of the
expression differences (or unchanged results) in the QPCR results
agreed with the microarray results, even when the microarray
results disagreed between the FFPE and fresh-frozen study. Similar
to previous observations [20,21], the magnitude of change was
often higher with the QPCR results than the microarray results
(Table 3). We conclude that microarray methods provide results
Table 3
Conﬁrmation of microarray results by QPCR.
Gene FFPE: colon tumor vs.
normal
Frozen: colon tumor vs.
normal
Microarray QPCR Microarray QPCR
BCL2L1 2.7a 3.0 2.4 6.0
CA1 −46 −1200 −53 −3800
CEACAM1 −4.8 −3.0 −3.2 −5.4
COL11A1 18.5 2.3 4.0 7.2
COL1A2 7.0 3.3 ncb nc
COL3A1 5.2 760 nc nc
COL5A1 6.2 740 nc −2.1
CYR61 3.0 3.9 −3.0 −6.5
EGR1 −2.9 −2.0 −3.0 −6.9
MMP11 4.0 43 4.0 7.4
MMP14 5.2 5800 nc nc
MMP9 8.8 2.7 nc nc
PECAM1 2.4 56 −2.4 −3.8
SRGN 3.0 7.4 −4.0 −6.7
WISP1 9.6 7.2 nc nc
a Fold changes in tumor tissue compared to normal tissue is shown for RNA from
FFPE samples and frozen samples. For microarrays, signiﬁcant differences (based on a
5% FDR cut-off) are shown, with averages given when more than 1 probe set is
signiﬁcant.
b The nc indicates no change where the expression differences were not statistically
signiﬁcant and/or below a 2-fold difference.
Fig. 4. Rosetta Resolver ratio biosignature compare plots (cancer versus normal). Gene
biosignatures (Pb0.001 with a N2.0 fold-change in both) are compared directly for
results derived from tumor versus normal ratios to examine the consistency of the
results. From FFPE normal adjacent lung tissue, we isolated RNA from 2 consecutive sets
of sections using the RecoverAll technique and obtained expression proﬁles on arrays.
Results from these 2 arrays were mathematically combined in Resolver, and ratios
(Log10) were made to an array similarly prepared from the patient-matched lung sq
ca1 sample. A second array was prepared in the same manner from a set of sections
consecutive to the ﬁrst set from lung sq ca1. The 2 sets of “2 versus 1” ratios are
compared in A (FFPE versus. FFPE). The correlation between similarly generated ratios
for FFPE and matched frozen tissue is shown in B (FFPE versus frozen), and between 2
similarly matched frozen tissue sections, C (frozen versus frozen), is shown. For all
graphs, common signature genes have blue symbols, genes unique to the y-axis
signature have green symbols, genes unique to the x-axis signature have red symbols,
and anti-correlated genes have purple symbols.
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of conﬂicting results may in fact be due to real sample-to-sample
variation.Biological relevance of the colon and lung tumor FFPE signature genes
To investigate the relevance of the gene signatures derived from
the FFPE samples using these techniques, we combined the replicate
FFPE samples and analyzed the signature sets of genes regulated 2-
fold or more (and Pb0.001) from the lung tumor samples and from
the colon cancer samples using the Ingenuity Pathway Analysis (IPA)
software. A similar comparison was made with combined frozen
replicates. As expected, IPA identiﬁed cancer as the top pathway for
both of the tumor versus normal comparisons (Fig. 5), indicating that
results at the pathway level are comparable between the FFPE and
fresh-frozen samples. In addition, the differentially expressed signa-
ture genes between lung tumor and lung normal FFPE samples had 67
genes in the lung tumor biological disease function with a p-value of
3.8×10−12, while the differentially expressed signature genes
between colon tumor and colon normal FFPE samples had 95
signature genes in the colon cancer biological disease function with
a p-value of 7.5×10−15.
Discussion
Reliable gene expression data from FFPE samples has the potential
to be an extremely valuable resource as these historical samples are
often associated with a wealth of histological and pathology
information; however, to date, they have been under-utilized. Critical
to obtaining this information is the identiﬁcation of the best
techniques for RNA isolation, ampliﬁcation, and data generation that
work together optimally. Through an extensive test of combinations
of techniques, we have identiﬁed such an approach using either a
modiﬁed RecoverAll RNA isolation technique or the FormaPure
procedure in combination with the RampUP ampliﬁcation procedure
and Affymetrix U133A arrays. We found that the RNA yields were
optimal with the RecoverAll procedure when the tissue input was
kept to three to four slices 10 μm in thickness instead of the maximum
of eight sections. These techniques generated FFPE expression proﬁles
that were consistent with proﬁles from matched fresh-frozen
samples.
However, the quality of the RNA is still critical for reliable analysis
of FFPE samples [1,5–8,10,13]. Therefore, a key aspect of the
procedures in this study is the recovery during extraction and
ampliﬁcation of small RNA molecules in the various sample
puriﬁcation steps, as quite often, a substantial amount of the FFPE
Fig. 5. Biological function groups identiﬁed by tumor versus normal comparisons. The Bio Functional analysis tool of IPA identiﬁed the functions and diseases that were most
signiﬁcant to the differentially expressed (biosignature) genes in the lung tumor vs. normal adjacent lung tissue (A) and the colon tumor vs. normal adjacent colon tissue (B). The top
functions for the FFPE samples, RecoverAll (striped bars) and FormaPure (white bars) along with the results from the frozen tissue comparison (black bars) are shown. The p-values
are calculated using the Fisher's exact test for the chance that the genes appeared in the biosignature by chance alone.
346 L. Roberts et al. / Genomics 94 (2009) 341–348RNA is partially degraded, and subsequently smaller than intact RNA.
It is also critical to extract as much information as possible from the
partially degraded RNAs, requiring the use of random primers to
prime across the entire message in order to extract expression
information from both ends of the mRNA/cDNA. The RampUP
procedure has the advantages of using both random and dT primers
for the reverse transcription of the RNA sample and minimizing the
amount of hands on and puriﬁcation steps during the process of
amplifying through two rounds. This method is accomplished by
incorporation of tandem T3 and T7 RNA polymerase promoters on the
3′ end of the random/dT primed cDNA, optimizing the representation
of the original 5′ end of themolecule and thus minimizing some of the
3′ bias from the ampliﬁed target. For these FFPE samples, this
procedure was quite robust and reproducible, generating technical
replicates with correlation coefﬁcients in the range from 0.89 to 0.95.
Using a retrospective analysis of the array results in combination
with the upfront analysis of the RNA samples similar to techniques for
FFPE RNA quantiﬁcation [1,5,11,13], we have found that the extent to
which the RNA can be ampliﬁed by QPCR is a key parameter for
predicting which FFPE samples will be suited for analysis using our
approach. Samples that maintain this quality, even if partially
degraded, are likely to generate expression proﬁles that have
satisfactory quality control metrics and subsequently, reliable data.
If the RNA in the sample is severely degraded, or the RNA is modiﬁed
in such a way that it cannot be ampliﬁed by standard RT-QPCR
techniques, it is likely that the expression proﬁle information from
that sample will not be accessible using the techniques described in
this study. Speciﬁcally, we found that samples with clear 18S and 28Sribosomal RNA Bioanalyzer peaks (RIN scores greater than 4),
generate microarrays with greater than 35% of the probe sets detected
as present (usually greater than 50%, data not shown). Signiﬁcantly
degraded and modiﬁed samples, those without distinct 18S and 28S
ribosomal RNA Bioanalyzer peaks and dCt values for 28S greater than
15, had less than 35% probe sets detected as present on themicroarray
(Fig. 3). Importantly, when the dCt for 28S was less than 15, we were
able to generate data that was comparable to fresh-frozen samples,
even when distinct 18S and 28S rRNA bands were not detectable on
the Bioanalyzer.
When comparing RNA expression proﬁles between FFPE and
matched, fresh-frozen samples, we observed some variation (corre-
lation 0.82–0.89). However, a small portion of this variation can be
ascribed to technical variation from one replicate to another, as we
observed correlations of 0.99 and 0.98 between fresh-frozen and FFPE
replicates from adjacent sections. Some of the remaining variation in
expression between fresh-frozen and FFPE can be attributed to sample
heterogeneity, as tumor tissue is known to be heterogeneous. This is
caused by factors such as variation in the percent of the tissue that is
tumor, as well as variation in the speciﬁc cells that comprise the tumor
sample such as stromal cells, vascularization, and even necrotic cells.
Signiﬁcantly, other studies have found intra-tumor heterogeneity in
RNA expression proﬁles that could lead to the variation we observed
[17–19]. Our experiment with matched FFPE and fresh-frozen
samples is somewhatmore sensitive to this heterogeneity, as separate
parts of tumor are processed individually for the FFPE sample and the
“matched” fresh-frozen sample. In addition, because the outer edge of
the FFPE sample is exposed to more harsh conditions [5], the initial
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increasing the distance between the fresh-frozen sample and the
sections used for FFPE studies.
We conﬁrmed our microarray expression results for the FFPE and
fresh-frozen samples by running QPCR for several genes that were
differentially expressed between tumor and normal samples. While
the microarray results in some cases under-estimated the fold-change
differences between the samples compared to the QPCR results, as has
been previously observed [20,21], the QPCR results conﬁrmed the
microarray results. Signiﬁcantly, where there were observed differ-
ences in results between the FFPE and fresh-frozen samples, the QPCR
results agreed with the results obtained from each sample by
microarray, even when they contradicted each other. This implies
that the microarray techniques are reﬂective of the expression status
of the samples, and that at least some of the differences between the
FFPE results and the fresh-frozen results are due to true differences in
the samples and perhaps the heterogeneity of tumor samples.
Microarray studies with diseased tissue are often used to identify
differential biosignatures that distinguish the normal state from
diseased state. It is therefore critical that the expression biosignatures
identiﬁed by the FFPE techniques are reﬂective of the expression
differences between samples. We found signiﬁcant agreement
between the biosignatures identiﬁed by the FFPE samples and the
fresh-frozen samples. This is a true testament to the value of the
experimental strategies selected for RNA extraction, quality testing,
and ampliﬁcation/labeling for these studies. Furthermore, the
biosignature genes from both the FFPE colon and lung tumor versus
normal comparisons identiﬁed “Cancer” as the most signiﬁcantly
regulated pathway in IPA. The colon tumor versus normal biosigna-
ture had 95 genes from the cancer biological disease function in IPA,
and the lung tumor versus normal biosignature had 67 genes from the
cancer biological disease function in IPA. Therefore, we conclude that
the procedures we have identiﬁed for processing FFPE material for
Affymetrix microarrays faithfully reproduce expression signatures.
Further, having the ability to predict the inherent success of
expression proﬁling experiments with FFPE samples using the
analysis metrics retrospectively developed in this work will aid the
design and magnitude of future clinical studies. Future experiments
can now explore expression patterns from FFPE tissue, a rich source of
disease tissue that can now be investigated more thoroughly and the
results correlated to patient outcome.
Materials and methods
Tissue samples and RNA isolation
Matched frozen and FFPE tissues were obtained from the
Cooperative Human Tissue Network (CHTN) at the Ohio State
University. RNA was isolated from FFPE tissues using the RecoverAll
(Ambion, Austin TX), Paradise Whole Transcript RT Reagent system
(Version A, Arcturus Bioscience, Mountain View, CA), High Pure
Parafﬁn kit (Version 09\2005, Roche, Nutley, NJ), Purelink FFPE RNA
isolation kit (Invitrogen, Carlsbad, CA), and the FormaPure RNA
isolation kit (Agencourt Bioscience Corporation, Beverly MA) follow-
ing the manufacturer's recommended protocol, except for the
following modiﬁcations: 1). All tissue slices were cut by microtome,
transferred immediately to 2 ml DNase/RNase free polypropylene
microfuge tubes at quantities listed in Table 1. 2). All tissue sections
were deparafﬁnized with Hemo-De according to the High Pure
Parafﬁn protocol version 9/2005, except the sections for FormaPure
followed the manufacturer's protocol. 3). The DNase I concentration
and incubation time was doubled for RecoverAll, 4). We used 16 μl of
elution buffer pre-heated to 60 °C for the Paradise procedures. FFPE
samples with usage code I or I/A in Table 1 were isolated using
RecoverAll, Paradise Whole Transcript, High Pure, and Purelink, while
samples with usage code I/H were isolated using RecoverAll andFormaPure. RNA was isolated from approximately 50 mg matched
frozen tissues post rotor homogenization on ice in 2.0 ml Qiazol
(Qiagen, Valencia, CA) following the manufacturer's recommended
protocol, followed by column puriﬁcation with an RNeasy mini kit
(Qiagen, Valencia, CA).
RNA ampliﬁcation
RNA from frozen and matched FFPE tissues was ampliﬁed by the
RampUP kit following the manufacturer's protocol (Genisphere,
Hatﬁeld, PA). Twenty to twenty-ﬁve ng of each total RNA was reverse
transcribed for 1 h at 42 °C using 50 ng random 9-mer primer and
50 ng dT24V primer, 10 mM dNTP mix, T4 gene 32 protein (USB,
Cleveland, OH) and SuperScript II enzyme (Invitrogen, Carlsbad, CA).
The cDNA was puriﬁed with the RNeasy MinElute kit (Qiagen,
Valencia, CA) using a modiﬁed protocol that included a pre-wash of
the column with nuclease-free water. The cDNA was poly d(A) tailed
on the 3′ end for 2 min at 37 °C using 0.2 mM dATP and Terminal
Deoxynucleotidyl Transferase. A tandem T7 T3 dT oligo with a 3′
blocking group was hybridized to the 3′ dA tail of the cDNA by
incubating at 37 °C for 10 min. Klenow enzyme and 10 mM dNTP mix
were added, and the reaction incubated at room temperature for
30 min to generate a double stranded tandem T7 T3 promoter region
on the single stranded cDNA. The cDNA was in vitro transcribed
overnight at 37 °C using T7 RNA Polymerase and NTP Mix. The
resulting round 1 sense RNA was reverse transcribed for 1 h at 42 °C
using 500 ng random 9mer primer and 50 ng dT24V primer, 10 mM
dNTP mix, and SuperScript II enzyme. RNaseH was added and
incubated at 37 °C for 30 min to degrade the RNA from the RNA/
cDNA hybrid. A T3 oligo was hybridized to the 3′ complementary T3
sequence of the cDNA at 37 °C for 10 min, generating a double
stranded promoter region on the single stranded cDNA. The cDNAwas
in vitro transcribed overnight at 37 °C using T3 RNA Polymerase and
NTP mix. The resulting round-2 sense RNA was puriﬁed using the
RNeasy MinElute kit (Qiagen, Valencia CA) and quantiﬁed using a
NanoDrop spectrophotometer (NanoDrop, Wilmington, DE).
Round-2 sense RNA was labeled using the cDNA Synthesis Kit
(Genisphere, Hatﬁeld, PA) following the manufacturer's protocol.
Brieﬂy, 20 μg of round 2 sense RNAwas reverse transcribed for 2.5 h at
42 °C using 30 μg random 12-mer primer, 10 mM dATP, 10 mM dCTP,
10 mM dGTP, 2 mM dTTP, 1 mM biotin-16-dUTP and SuperScript II
enzyme. The template RNA was degraded by adding 0.5 M NaOH/
50 mM EDTA and incubating at 65 °C for 30 min. The reaction was
neutralized by adding 1 M Tris–HCl (pH 8) and biotin-labeled cDNA
was puriﬁed with microcon YM-50 columns (Millipore, Billerica, MA).
Microarray hybridization
Six micrograms of biotin-labeled cDNA was preconditioned in
fragmentation buffer in 40 μl according to Affymetrix standard RNA
fragmentation protocol. The reaction was then combined with 160 μl
of “100 Format” (Midi) hybridization buffer master mix to obtain
200 μl total volume, of which 140 μl was loaded into the HG-U133A 2.0
arrays, and hybridized at 48 °C for 16–17 h. Arrays were then washed,
stained, and scanned according to Midi format protocol (Affymetrix,
Santa Clara, CA).
Microarray data analysis
Themicroarray data ﬁles (.cel) were generatedwith GCOS (version
6.0) and analyzed to determine quality control metrics. The cel ﬁles
were loaded into Rosetta Resolver (Rosetta Biosoftware, Seattle, WA)
for further analysis. The intensity values for all probe sets were
normalized using the Rosetta algorithm and ratios of colon normal
versus colon cancer and lung normal adjacent tissue (NAT) versus
lung cancer probe sets, were generated in a Resolver Experimental
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intensity proﬁles of pairs of arrays were derived from Resolver's
correlation plots to determine the inﬂuences of RNA isolation
procedure, tissue type, and tissue heterogeneity on microarray
reproducibility. For determination of biological relevance, gene
biosignatures were deﬁned from the normal versus cancer ratios
using a p-value cut-off of less than 0.001, and a fold-change cut-off of
N2.0. Comparison plots of probe set biosignatures were generated
using Resolver's comparison plot function. Separate gene biosigna-
tures were made for each biological replicate of tumor array versus
the combination of 2 normal tissue arrays to observe the biological
variance between tissue sections of the same block. The biological
function and canonical pathway analyses were generated through the
use of Ingenuity Pathways Analysis (Ingenuity Systems®, www.
ingenuity.com), with a p-value cut-off of b0.001, and a fold-change
cut-off of N2.0.
QPCR, spectrophotometric, Bioanalyzer, and QPCR techniques for RNA
quality assessment
RNA yield and purity were determined by spectrophotometry
(A260/A280) using the NanoDrop 1000 instrument (Thermo Scien-
tiﬁc, Wilmington DE). RNA integrity was assessed by measuring the
molecular weight proﬁles of 1 μl sample RNA on the Agilent 2100
Bioanalyzer instrument using the RNA 6000 Pico kit (Agilent
Technologies, Santa Clara, CA) according to the manufacturer's
protocol. To determine RNA quality by QPCR, 50 ng of RNA in a10 μl
total volume was added to 1 μl of T7-Oligo (dT) primer (5 μM ﬁnal
concentration), and incubated at 70 °C for 10 min. The reaction was
cooled on ice, and 9 μl of a RT master mix (comprised of 4 μl ﬁrst
strand buffer, 2 μl 0.1 M DTT, 1 μl RNAse Out, 1 μl dNTP mix, and 1 μl
Superscript II) was added. The 20 μl reverse transcription reaction was
incubated at 42 °C for 1.5 h. The reaction was cooled to 4 °C for 10 min
and 1 μl of RNaseH (Invitrogen, Carslbad, CA) was added. The reaction
was mixed gently, and incubated at 37 °C for 30 min. The reaction was
stopped by heating to 95 °C for 5 min, then cooled to 4 °C for at least
1 min. As a standard, 100 ng Universal cell line control RNA
(Stratagene, La Jolla, CA) was reverse transcribed separately and
used to prepare a standard curve and for delta Ct analysis.
The Beta Actin (ACTB) 3′ and 5′ QPCR assays were performed as
described in the Arcturus Paradise Sample Assessment Protocol
(pages 5–3 to 5–9 in the Paradise sample quality assessment kit
manual). ACTB 3′/5′ ratios were calculated by comparing the ratio of
the ACTB 3′ amplicon to the 5′ amplicon quantiﬁcation values
generated against a Universal cell line control. Values for the delta
Ct was calculated using the formula: Ct FFPE−Ct 100 ng Universal cell
line control.
For 28S delta Ct analysis: 8 μl cDNA from above was combinedwith
12 μl mastermix containing 400 nM forward and reverse primers (28S
Forward Primer: 5′-CGGTACACCTGTCAAACGGTAA-'3, 28S Reverse
Primer: 5′ TCTGCTCCACGGGAGGTT '3) and 1× Quantitect Sybr Green
PCR buffer (Qiagen, PN 204143). Thermal cycling carried out in an ABI
7300 thermocycler using the following conditions: 1 cycle 50 °C for
2min, 95 °C for 15min, 40 cycles of 94 °C for 15 s, 30 °C for 58 s, read at
72 °C for 35 s. The 28S 5′dCt was calculated by the formula: Ct FFPE
−Ct 50 ng Universal cell line control for the 28S amplicon.
For microarray expression proﬁle validation experiments: 1.5 μg of
each unampliﬁed RNA was reverse transcribed for 2 h at 42 °C using
3 μg random 9mer primer, 10 mM dNTP mix, and SuperScript II
enzyme. The volume of cDNAwas adjusted to 220 μL by adding water.
In eachwell of a 96-well plate, 2 μL of the diluted cDNAwas added to a
23 μL master mix of the appropriate10× QuantiTect Primer Assay(Supplementary Table S4), 2× Quantitect SYBR Green PCR Master Mix
(Qiagen, Valencia, CA), and water. QPCR was conducted on the 7300
Real Time PCR System (Applied Biosystems) using an initial activation
at 95 °C for 15 min, then 40 cycles of denaturation at 94 °C for 15 s,
annealing at 55 °C for 30 s , extension and ﬂuorescence data collection
at 72 °C for 30 s . Relative quantiﬁcation was performed using the
delta delta Ct method relative to 18S RNA as a control.
Acknowledgments
The authors wish to acknowledge Paul Kroeger and Brian Spear
(Abbott Laboratories) for their critical comments and feedback.
Disclosure statement: J.B., K.S, and R.G. are employed by Genisphere.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2009.07.007.
References
[1] S.K. Penland, et al., RNA expression analysis of formalin-ﬁxed parafﬁn-embedded
tumors, Lab. Invest. 87 (2007) 383–391.
[2] N. Masuda, T. Ohnishi, S. Kawamoto, M. Monden, K. Okubo, Analysis of chemical
modiﬁcation of RNA from formalin-ﬁxed samples and optimization of molecular
biology applications for such samples, Nucleic Acids Res. 27 (1999) 4436–4443.
[3] M. Srinivasan, D. Sedmak, S. Jewell, Effect of ﬁxatives and tissue processing on the
content and integrity of nucleic acids, Am. J. Pathol. 161 (2002) 1961–1971.
[4] M. Benchekroun, et al., Impact of ﬁxative on recovery of mRNA from parafﬁn-
embedded tissue, Diagn. Mol. Pathol. 13 (2004) 116–125.
[5] S. von Ahlfen, A. Missel, K. Bendrat, M. Schlumpberger, Determinants of RNA
quality from FFPE samples, PLoS ONE 2 (2007) e1261.
[6] M.S. Scicchitano, et al., Preliminary comparison of quantity, quality, and
microarray performance of RNA extracted from formalin-ﬁxed, parafﬁn-embed-
ded, and unﬁxed frozen tissue samples, J. Histochem. Cytochem. 54 (2006)
1229–1237.
[7] R.A. Coudry, et al., Successful application of microarray technology to micro-
dissected formalin-ﬁxed, parafﬁn-embedded tissue, J. Mol. Diagn. 9 (2007) 70–79.
[8] T. Haque, et al., Gene expression proﬁling from formalin-ﬁxed parafﬁn-embedded
tumors of pediatric glioblastoma, Clin. Cancer Res. 13 (2007) 6284–6292.
[9] B. Furusato, et al., Transcriptome analyses of benign and malignant prostate
epithelial cells in formalin-ﬁxed parafﬁn-embedded whole-mounted radical
prostatectomy specimens, Prostate Cancer Prostatic Dis. 11 (2008) 194–197.
[10] K.M. Linton, et al., Acquisition of biologically relevant gene expression data by
Affymetrix microarray analysis of archival formalin-ﬁxed parafﬁn-embedded
tumours, Br. J. Cancer 98 (2008) 1403–1414.
[11] M. Ravo, et al., Quantitative expression proﬁling of highly degraded RNA from
formalin-ﬁxed, parafﬁn-embedded breast tumor biopsies by oligonucleotide
microarrays, Lab. Invest. 88 (2008) 430–440.
[12] P.K. Srivastava, et al., A cut-off based approach for gene expression analysis of
formalin-ﬁxed and parafﬁn-embedded tissue samples, Genomics 91 (2008)
522–529.
[13] A. Oberli, et al., Expression proﬁling with RNA from formalin-ﬁxed, parafﬁn-
embedded material, BMC Med. Genomics 1 (2008) 9.
[14] L.A. Goff, et al., Evaluation of sense-strand mRNA ampliﬁcation by comparative
quantitative PCR, BMC Genomics 5 (2004) 76.
[15] J.M. Miller, M.D. Miller, P.E. Driscoll, P. Miller, Biodegradable, effective substitute
for xylene in the Ehrlich indole procedure, J. Clin. Microbiol. 32 (1994)
2028–2030.
[16] A. Ribeiro-Silva, H. Zhang, S.S. Jeffrey, RNA extraction from ten year old formalin-
ﬁxed parafﬁn-embedded breast cancer samples: a comparison of column
puriﬁcation and magnetic bead-based technologies, BMC Mol. Biol. 8 (2007) 118.
[17] P. Francis, et al., Intratumor versus intertumor heterogeneity in gene expression
proﬁles of soft-tissue sarcomas, Genes Chromosomes Cancer 43 (2005) 302–308.
[18] B. Bachtiary, et al., Gene expression proﬁling in cervical cancer: an exploration of
intratumor heterogeneity, Clin. Cancer Res. 12 (2006) 5632–5640.
[19] K.M. Jochumsen, Q. Tan, B. Holund, T.A. Kruse, O. Mogensen, Gene expression in
epithelial ovarian cancer: a study of intratumor heterogeneity, Int. J. Gynecol
Cancer 17 (2007) 979–985.
[20] T. Yuen, E. Wurmbach, R.L. Pfeffer, B.J. Ebersole, S.C. Sealfon, Accuracy and
calibration of commercial oligonucleotide and custom cDNA microarrays, Nucleic
Acids Res. 30 (2002) e48.
[21] P.B. Dallas, et al., Gene expression levels assessed by oligonucleotide microarray
analysis and quantitative real-time RT-PCR — how well do they correlate? BMC
Genomics 6 (2005) 59.
